Evidence map›Paper›PMID 37755665›Full record

ArticleCancer2024

Annual Report to the Nation on the Status of Cancer, part 2: Early assessment of the COVID-19 pandemic's impact on cancer diagnosis.

Serban Negoita, Huann-Sheng Chen, Pamela V Sanchez, Recinda L Sherman, S Jane Henley, Rebecca L Siegel, Hyuna Sung, Susan Scott, Vicki B Benard, Betsy A Kohler and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. COVID-19 and Lung Cancer Interactions: A Literature Review.Medical sciences (Basel, Switzerland) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Disparities in Cancer Stage Shifts Associated with the COVID-19 Pandemic in California, 2020 to 2021.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  16. Article
  17. Article
  18. Thyroid Cancer Incidence During 2020 to 2021 COVID-19 Variant Waves.JAMA otolaryngology-- head & neck surgery · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Serban NegoitaDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-9327-9519
Huann-Sheng ChenDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
Pamela V SanchezDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-3455-1471
Recinda L ShermanNorth American Association of Central Cancer Registries, Springfield, Illinois, USA.
S Jane HenleyDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-2420-306X
Rebecca L SiegelSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, USA.
Hyuna SungSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0002-8021-5997
Susan ScottDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-5881-8313
Vicki B BenardDivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-1989-0819
Betsy A KohlerNorth American Association of Central Cancer Registries, Springfield, Illinois, USA.
Ahmedin JemalSurveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, USA.ORCID 0000-0002-0000-4111
Kathleen A CroninDivision of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
National Cancer Institute · USAmerican Cancer Society · USCenters for Disease Control and Prevention · USNorth American Association of Central Cancer Registries · US

Funding

Intramural NIH HHS Z99 CA999999NCCDPHP CDC HHSNCI NIH HHS
6 · The paper itself

Abstract

backgroundWith access to cancer care services limited because of coronavirus disease 2019 control measures, cancer diagnosis and treatment have been delayed. The authors explored changes in the counts of US incident cases by cancer type, age, sex, race, and disease stage in 2020.

methodsData were extracted from selected US population-based cancer registries for diagnosis years 2015-2020 using first-submission data from the North American Association of Central Cancer Registries. After a quality assessment, the monthly numbers of newly diagnosed cancer cases were extracted for six cancer types: colorectal, female breast, lung, pancreas, prostate, and thyroid. The observed numbers of incident cancer cases in 2020 were compared with the estimated numbers by calculating observed-to-expected (O/E) ratios. The expected numbers of incident cases were extrapolated using Joinpoint trend models.

resultsThe authors report an O/E ratio <1.0 for major screening-eligible cancer sites, indicating fewer newly diagnosed cases than expected in 2020. The O/E ratios were lowest in April 2020. For every cancer site except pancreas, Asians/Pacific Islanders had the lowest O/E ratio of any race group. O/E ratios were lower for cases diagnosed at localized stages than for cases diagnosed at advanced stages.

conclusionsThe current analysis provides strong evidence for declines in cancer diagnoses, relative to the expected numbers, between March and May of 2020. The declines correlate with reductions in pathology reports and are greater for cases diagnosed at in situ and localized stage, triggering concerns about potential poor cancer outcomes in the coming years, especially in Asians/Pacific Islanders. PLAIN LANGUAGE SUMMARY: To help control the spread of coronavirus disease 2019 (COVID-19), health care organizations suspended nonessential medical procedures, including preventive cancer screening, during early 2020. Many individuals canceled or postponed cancer screening, potentially delaying cancer diagnosis. This study examines the impact of the COVID-19 pandemic on the number of newly diagnosed cancer cases in 2020 using first-submission, population-based cancer registry database. The monthly numbers of newly diagnosed cancer cases in 2020 were compared with the expected numbers based on past trends for six cancer sites. April 2020 had the sharpest decrease in cases compared with previous years, most likely because of the COVID-19 pandemic.

Indexed as

COVID-19NeoplasmsCOVID-19 TestingFemaleHumansMalePandemicsRegistriescancer incidencecancer stagecancer surveillancecoronavirus disease 2019 (COVID-19)observed-to-expectedpathology reports

Identifiers

PMID37755665
PMCPMC10841454
OpenAlexW4387077860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.